Andrea Sartore-Bianchi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7554181/publications.pdf

Version: 2024-02-01

192	26,149	26630 56	6471 157
papers	citations	h-index	g-index

199	199	199	25144
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases. Cancers, 2022, 14, 241.	3.7	14
2	Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management. ESMO Open, 2022, 7, 100338.	4.5	14
3	The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives. Cancer Treatment Reviews, 2022, 104, 102351.	7.7	34
4	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. Oncologist, 2022, 27, e29-e36.	3.7	3
5	Efficacy of retreatment with oxaliplatin-based regimens in metastatic colorectal cancer patients: The RETROX-CRC retrospective study.. Journal of Clinical Oncology, 2022, 40, 127-127.	1.6	0
6	Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment. European Journal of Cancer, 2022, 163, 16-25.	2.8	17
7	Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study. Cancers, 2022, 14, 1197.	3.7	9
8	Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review. Cancers, 2022, 14, 1666.	3.7	15
9	Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients. European Journal of Cancer, 2022, 167, 175-176.	2.8	1
10	Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. British Journal of Cancer, 2022, 127, 394-407.	6.4	41
11	ALK Inhibitors in Patients With ALK Fusionâ€“Positive GI Cancers: An International Data Set and a Molecular Case Series. JCO Precision Oncology, 2022, 6, e2200015.	3.0	8
12	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. Cancer Discovery, 2022, 12, 1656-1675.	9.4	48
13	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. British Journal of Cancer, 2022, 127, 957-967.	6.4	6
14	Application of histology-agnostic treatments in metastatic colorectal cancer. Digestive and Liver Disease, 2022, 54, 1291-1303.	0.9	5
15	The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. Cancers, 2021, 13, 137.	3.7	46
16	Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas. Clinical Cancer Research, 2021, 27, 3126-3140.	7.0	11
17	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 2505-2514.	7.0	14
18	Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. Targeted Oncology, 2021, 16, 309-324.	3.6	14

#	Article	IF	Citations
19	Personalized therapeutic strategies in HER2-driven gastric cancer. Gastric Cancer, 2021, 24, 897-912.	5.3	6
20	Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ. Nature Communications, 2021, 12, 2340.	12.8	43
21	Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repairâ€“Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. Cancer Discovery, 2021, 11, 1923-1937.	9.4	48
22	Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.. Journal of Clinical Oncology, 2021, 39, 3506-3506.	1.6	53
23	Relationships Between KÃ¶hne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2021, , .	2.3	1
24	Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression. Nature Immunology, 2021, 22, 735-745.	14.5	36
25	Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis. Cancers, 2021, 13, 2265.	3.7	14
26	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 779-789.	10.7	234
27	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers, 2021, 13, 2638.	3.7	32
28	Strategies to tackle RAS-mutated metastatic colorectal cancer. ESMO Open, 2021, 6, 100156.	4.5	38
29	Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. JCO Precision Oncology, 2021, 5, 1192-1199.	3.0	5
30	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clinical Cancer Research, 2020, 26, 1372-1384.	7.0	66
31	Breaking Barriers in HER2+ Cancers. Cancer Cell, 2020, 38, 317-319.	16.8	7
32	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open, 2020, 5, e000911.	4.5	94
33	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. Annals of Oncology, 2020, 31, 1135-1147.	1.2	58
34	Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. Cancer Treatment Reviews, 2020, 91, 102112.	7.7	29
35	Radiomics predicts response of individual <scp>HER2</scp>â€amplified colorectal cancer liver metastases in patients treated with <scp>HER2</scp>â€targeted therapy. International Journal of Cancer, 2020, 147, 3215-3223.	5.1	27
36	CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. International Journal of Molecular Sciences, 2020, 21, 6350.	4.1	34

#	Article	IF	Citations
37	507P Central nervous system recurrence in HER2-positive metastatic colorectal cancer. Annals of Oncology, 2020, 31, S455.	1.2	2
38	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. British Journal of Cancer, 2020, 123, 403-409.	6.4	93
39	The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review. Frontiers in Oncology, 2020, 10, 533.	2.8	17
40	Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer. JAMA Oncology, 2020, 6, 927.	7.1	20
41	Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. Expert Review of Anticancer Therapy, 2020, 20, 333-341.	2.4	26
42	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, 256-262.e2.	2.3	56
43	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. European Journal of Cancer, 2020, 135, 230-239.	2.8	11
44	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 1017-1024.	7.0	22
45	Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases. European Radiology Experimental, 2020, 4, 62.	3.4	29
46	The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.. Journal of Clinical Oncology, 2020, 38, TPS4124-TPS4124.	1.6	14
47	The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 1510.	7.1	1
48	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. Clinical Cancer Research, 2019, 25, 6243-6259.	7.0	42
49	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the â€˜BRAF BeCoolâ€™ study. European Journal of Cancer, 2019, 118, 121-130.	2.8	51
50	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Frontiers in Oncology, 2019, 9, 622.	2.8	22
51	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. Drugs, 2019, 79, 1375-1394.	10.9	48
52	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 1268.	7.1	70
53	Adaptive mutability of colorectal cancers in response to targeted therapies. Science, 2019, 366, 1473-1480.	12.6	290
54	Liquid biopsy for rectal cancer: A systematic review. Cancer Treatment Reviews, 2019, 79, 101893.	7.7	28

#	Article	IF	Citations
55	SP-0453 Targeting DNA repair to improve immunesurveillance and restrict cancer growth. Radiotherapy and Oncology, 2019, 133, S235-S236.	0.6	0
56	Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. Journal of Clinical Oncology, 2019, 37, 3099-3110.	1.6	65
57	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cellâ€“Intrinsic Transcriptional MSI Traits. Cancer Research, 2019, 79, 5884-5896.	0.9	53
58	Increased incidence of colon cancer among individuals younger than 50 years: A 17 years analysis from the cancer registry of the municipality of Milan, Italy. Cancer Epidemiology, 2019, 60, 134-140.	1.9	34
59	Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression. Cancer Immunology Research, 2019, 7, 751-758.	3.4	29
60	Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. Clinical Cancer Research, 2019, 25, 3046-3053.	7.0	112
61	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. Oncologist, 2019, 24, 1395-1402.	3.7	95
62	Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. ESMO Open, 2019, 4, e000572.	4.5	27
63	Concurrent Small-Cell Transformation and Emergence of Trans-C797S and T790M Mutations Under Sequential Treatment With EGFR Inhibitors in Lung Adenocarcinoma. JCO Precision Oncology, 2019, 3, 1-5.	3.0	4
64	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. Cancer Treatment Reviews, 2019, 73, 41-53.	7.7	69
65	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. Clinical Colorectal Cancer, 2019, 18, e117-e129.	2.3	53
66	Earlyâ€onset colorectal cancer in young individuals. Molecular Oncology, 2019, 13, 109-131.	4.6	365
67	A randomized phase II trial of second-line CAPTEM versus FOLFIRI in MGMT methylated, RAS mutated metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology, 2019, 37, 3509-3509.	1.6	1
68	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.. Journal of Clinical Oncology, 2019, 37, TPS2659-TPS2659.	1.6	10
69	Mutational signatures of early-onset colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15113-e15113.	1.6	0
70	Radiomics features on CT scans to predict response to HER2-targeted therapy of hepatic metastases from colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15086-e15086.	1.6	0
71	Abstract LB-299: A comprehensive platform of patient-derived xenografts and matched cell lines mirrors the genomic landscape of colorectal cancer. , 2019, , .		0
72	Abstract A120: Adaptive mutability of colorectal cancers in response to targeted therapies. , 2019, , .		0

#	Article	IF	Citations
73	Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Annals of Oncology, 2018, 29, 1108-1119.	1.2	177
74	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open, 2018, 3, e000299.	4.5	29
75	Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET). Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 114-116.	1.5	4
76	Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer. JAMA Oncology, 2018, 4, 19.	7.1	16
77	Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Annals of Oncology, 2018, 29, 119-126.	1.2	76
78	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 80-83.	2.3	40
79	TRKA expression and NTRK1 gene copy number across solid tumours. Journal of Clinical Pathology, 2018, 71, 926-931.	2.0	12
80	The right chance for temozolomide in metastatic colorectal cancer?. Annals of Oncology, 2018, 29, 1618-1619.	1.2	0
81	Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer. Annals of Oncology, 2018, 29, 2143-2144.	1.2	13
82	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. Cancer Cell, 2018, 34, 148-162.e7.	16.8	129
83	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. Nature Communications, 2018, 9, 2287.	12.8	18
84	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut, 2018, 67, 1995-2005.	12.1	188
85	Abstract 5723: Inactivation of DNA repair triggers neoantigen generation and impairs tumor growth. Cancer Research, 2018, 78, 5723-5723.	0.9	5
86	First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.. Journal of Clinical Oncology, 2018, 36, 3505-3505.	1.6	23
87	Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 3506-3506.	1.6	8
88	Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study.. Journal of Clinical Oncology, 2018, 36, 581-581.	1.6	3
89	Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the â€œBRAF, BeCoolâ€•platform.. Journal of Clinical Oncology, 2018, 36, 639-639.	1.6	2
90	Abstract A087: Empowering precision medicine in metastatic colorectal cancer: preliminary results from the FUNNEL platform. , 2018, , .		0

#	Article	IF	Citations
91	Abstract A089: Exploiting clonal evolution and liquid biopsy to overcome resistance to anti-EGFR treatment in metastatic colorectal cancer: the CHRONOS trial. , 2018, , .		7
92	Abstract 2848: Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. , 2018, , .		1
93	Abstract 2743: Accumulation of predicted neoantigens by MMR deficiency triggered by temozolomide treatment of human colorectal cancer. , 2018, , .		0
94	Abstract 205: Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. , 2018, , .		0
95	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clinical Cancer Research, 2017, 23, 3657-3666.	7.0	53
96	Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. Clinical Colorectal Cancer, 2017, 16, e153-e163.	2.3	110
97	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discovery, 2017, 7, 400-409.	9.4	647
98	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	183
99	Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. Annals of Oncology, 2017, 28, 1302-1308.	1.2	32
100	Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. Handbook of Experimental Pharmacology, 2017, 249, 145-159.	1.8	1
101	Molecular Markers Beyond Microsatellite Instability for Assessing Prognosis in Early-Stage Colorectal Cancer. JAMA Oncology, 2017, 3, 481.	7.1	1
102	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents inÂmetastatic colorectal cancer patients. European Journal of Cancer, 2017, 71, 43-50.	2.8	27
103	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature, 2017, 552, 116-120.	27.8	480
104	Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. Targeted Oncology, 2017, 12, 525-533.	3.6	15
105	Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer. Cancer Research, 2017, 77, CT005-CT005.	0.9	19
106	Abstract 3834: Tracking CAD-ALK gene translocation in urine and plasma of a colorectal cancer patient treated with ALK blockade. , 2017, , .		0
107	Abstract 2913: Emergence ofRASorEGFRmutant clones affects duration of response to EGFR blockade in colorectal cancers. , 2017, , .		0
108	NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open, 2016, 1, e000023.	4.5	444

#	Article	IF	Citations
109	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT) Tj ETQq1 1 0.784314 rgBT /Ove	4.8	2
110	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nature Communications, 2016, 7, 13665.	12.8	170
111	Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. ESMO Open, 2016, 1, e000079.	4.5	3
112	Pertuzumab and trastuzumab-emtansine in HER2 positive metastatic colorectal cancer: the HERACLES B TRIAL. Annals of Oncology, 2016, 27, iv47.	1.2	2
113	Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Annals of Oncology, 2016, 27, 1456-1466.	1.2	51
114	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 738-746.	10.7	778
115	Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. Cancer Treatment Reviews, 2016, 51, 54-62.	7.7	24
116	The FUNNEL: a precision medicine project for metastatic colorectal cancer. Annals of Oncology, 2016, 27, iv48.	1.2	0
117	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. Cancer Research, 2016, 76, 4504-4515.	0.9	91
118	Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast. Journal of Clinical Oncology, 2016, 34, e54-e56.	1.6	10
119	Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study. Clinical Colorectal Cancer, 2016, 15, 213-221.	2.3	31
120	Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1062-1067.	1.2	35
121	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discovery, 2016, 6, 147-153.	9.4	338
122	Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Cancer Discovery, 2016, 6, 36-44.	9.4	258
123	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	6.3	111
124	Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System. American Journal of Hypertension, 2016, 29, 158-162.	2.0	23
125	Abstract 878: Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. , 2016, , .		1
126	Abstract CT082: Pertuzumab and trastuzumab-emtansine in HER2-positive colorectal cancer: the HERACLES B trial. , 2016, , .		3

#	Article	IF	Citations
127	HER2 amplification as a â€˜molecular baitâ€™ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. Journal of Clinical Oncology, 2016, 34, TPS774-TPS774.	1.6	18
128	The FUNNEL: A molecular multiplex triage for precision medicine in metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, TPS3636-TPS3636.	1.6	0
129	Germ Cell Tumors Overexpress the Candidate Therapeutic target Cyclin B1 Independently of p53 function. International Journal of Biological Markers, 2015, 30, 275-281.	1.8	3
130	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine, 2015, 21, 795-801.	30.7	809
131	Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. British Journal of Cancer, 2015, 113, 1730-1734.	6.4	65
132	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Annals of Oncology, 2015, 26, 2092-2097.	1.2	137
133	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Annals of Oncology, 2015, 26, 1994-1999.	1.2	105
134	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nature Communications, 2015, 6, 7002.	12.8	251
135	The genomic landscape of response to EGFR blockade in colorectal cancer. Nature, 2015, 526, 263-267.	27.8	398
136	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Modern Pathology, 2015, 28, 1481-1491.	5.5	226
137	Alka-372-001: First-in-human, phase I study of entrectinib â€“ an oral pan-trk, ROS1, and ALK inhibitor â€“ in patients with advanced solid tumors with relevant molecular alterations.. Journal of Clinical Oncology, 2015, 33, 2517-2517.	1.6	27
138	Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. Journal of Clinical Oncology, 2015, 33, 3508-3508.	1.6	27
139	Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.. Journal of Clinical Oncology, 2015, 33, 565-565.	1.6	2
140	Phase II study of temozolomide (TMZ) in metastatic colorectal cancer (mCRC) patients molecularly selected by MGMT promoter hypermethylation.. Journal of Clinical Oncology, 2015, 33, 583-583.	1.6	1
141	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget, 2015, 6, 31604-31612.	1.8	30
142	Regorafenib in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2014, 14, 255-265.	2.4	20
143	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	12.4	3,665
144	Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer. Science Translational Medicine, 2014, 6, 224ra26.	12.4	228

#	Article	IF	Citations
145	Acquired resistance to EGFRâ€targeted therapies inÂcolorectal cancer. Molecular Oncology, 2014, 8, 1084-1094.	4.6	121
146	The TPM3â€NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Molecular Oncology, 2014, 8, 1495-1507.	4.6	128
147	Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer. Journal of the National Cancer Institute, 2014, 106, djt322.	6.3	76
148	Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. Cancer Discovery, 2014, 4, 1269-1280.	9.4	415
149	Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.. Journal of Clinical Oncology, 2014, 32, 2502-2502.	1.6	18
150	Abstract 2829: Identification of the role of SRBC methylation-associated gene silencing as predictive factor of oxaliplatin secondary resistance in metastasic colorectal cancer patients. , 2014, , .		0
151	KRAS gene amplification in colorectal cancer and impact on response to EGFRâ€targeted therapy. International Journal of Cancer, 2013, 133, 1259-1265.	5.1	154
152	Regorafenib for metastatic colorectal cancer. Lancet, The, 2013, 381, 1537.	13.7	15
153	Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. Cancer, 2013, 119, 3429-3435.	4.1	26
154	Magnetic Resonance Imaging as an Early Indicator of Clinical Outcome in Patients With Metastatic Colorectal Carcinoma Treated With Cetuximab or Panitumumab. Clinical Colorectal Cancer, 2013, 12, 45-53.	2.3	13
155	Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discovery, 2013, 3, 658-673.	9.4	585
156	Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer. Clinical Cancer Research, 2013, 19, 2265-2272.	7.0	96
157	Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer. PLoS ONE, 2013, 8, e62264.	2.5	21
158	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification).. Journal of Clinical Oncology, 2013, 31, TPS3648-TPS3648.	1.6	7
159	Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?. Annals of Translational Medicine, 2013, 1, 12.	1.7	4
160	Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. Journal of Clinical Pathology, 2012, 65, 218-223.	2.0	35
161	Correction: Figure 4. Journal of Clinical Pathology, 2012, 65, 674-674.	2.0	0
162	Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation?. Current Colorectal Cancer Reports, 2012, 8, 272-276.	0.5	1

#	Article	IF	Citations
163	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature, 2012, 486, 532-536.	27.8	1,605
164	A Molecularly Annotated Platform of Patient-Derived Xenografts (â€œXenopatientsâ€) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. Cancer Discovery, 2011, 1, 508-523.	9.4	818
165	Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Targeted Oncology, 2010, 5, 19-28.	3.6	27
166	Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA - Journal of the American Medical Association, 2010, 304, 1812.	7.4	663
167	Response: Re: Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2010, 102, 573-575.	6.3	1
168	Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer Treatment Reviews, 2010, 36, S1-S5.	7.7	37
169	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncology, The, 2010, 11, 753-762.	10.7	1,915
170	Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer. PLoS ONE, 2009, 4, e7287.	2.5	241
171	PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies. Cancer Research, 2009, 69, 1851-1857.	0.9	711
172	Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptorâ€“Targeted Therapy in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2009, 101, 1308-1324.	6.3	486
173	Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: a case report and review of the literature. Targeted Oncology, 2008, 3, 127-130.	3.6	5
174	EGFR FISH in colorectal cancer: what is the current reality?. Lancet Oncology, The, 2008, 9, 402-403.	10.7	41
175	Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 5705-5712.	1.6	1,540
176	Mutations of KRAS and BRAF in Primary and Matched Metastatic Sites of Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 4217-4219.	1.6	218
177	Bortezomib Inhibits Nuclear Factor-ÎºBâ€“Dependent Survival and Has Potent In vivo Activity in Mesothelioma. Clinical Cancer Research, 2007, 13, 5942-5951.	7.0	90
178	Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab. Current Cancer Therapy Reviews, 2007, 3, 249-254.	0.3	0
179	Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab. Journal of Clinical Oncology, 2007, 25, 3238-3245.	1.6	321
180	Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Antiâ€“Epidermal Growth Factor Receptor Antibody Therapies. Cancer Research, 2007, 67, 2643-2648.	0.9	801

#	Article	IF	Citations
181	Cetuximab for treatment of metastatic colorectal cancer. Annals of Oncology, 2006, 17, vii66-vii67.	1.2	10
182	Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer. Annals of Oncology, 2006, 17, ii49-ii51.	1.2	4
183	Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. Annals of Oncology, 2005, 16, 1848-1849.	1.2	28
184	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncology, The, 2005, 6, 279-286.	10.7	924
185	Raltitrexedâ€“Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer, 2005, 48, 429-434.	2.0	51
186	Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. Oncology Reports, 2005, 13, 689-95.	2.6	5
187	Gemcitabine and oxaliplatin in the treatment of patients with immunotherapyâ€resistant advanced renal cell carcinoma. Cancer, 2004, 100, 2132-2138.	4.1	24
188	Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients. Oncology Reports, 2004, 12, 855-9.	2.6	2
189	Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: A possible mechanism of interleukin-2-mediated cytotoxicity?. Lung Cancer, 2002, 38, 159-162.	2.0	8
190	Optimal CD34+ Cell Dose in Autologous Peripheral-Blood Stem-Cell Transplantation. Journal of Clinical Oncology, 2000, 18, 3319-3320.	1.6	18
191	Low doses of subcutaneous interleukin-2 plus interferon-Î± do not induce thyroid function alterations in advanced renal cell carcinoma patients. Oncology Reports, 0, , .	2.6	0
192	Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. Oncology Reports, 0, , .	2.6	3